These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 30585395)

  • 21. 7,8-dihydroxyflavone ameliorates cognitive and motor deficits in a Huntington's disease mouse model through specific activation of the PLCγ1 pathway.
    García-Díaz Barriga G; Giralt A; Anglada-Huguet M; Gaja-Capdevila N; Orlandi JG; Soriano J; Canals JM; Alberch J
    Hum Mol Genet; 2017 Aug; 26(16):3144-3160. PubMed ID: 28541476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.
    Peng Q; Masuda N; Jiang M; Li Q; Zhao M; Ross CA; Duan W
    Exp Neurol; 2008 Mar; 210(1):154-63. PubMed ID: 18096160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TRiC subunits enhance BDNF axonal transport and rescue striatal atrophy in Huntington's disease.
    Zhao X; Chen XQ; Han E; Hu Y; Paik P; Ding Z; Overman J; Lau AL; Shahmoradian SH; Chiu W; Thompson LM; Wu C; Mobley WC
    Proc Natl Acad Sci U S A; 2016 Sep; 113(38):E5655-64. PubMed ID: 27601642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.
    McBride JL; Ramaswamy S; Gasmi M; Bartus RT; Herzog CD; Brandon EP; Zhou L; Pitzer MR; Berry-Kravis EM; Kordower JH
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9345-50. PubMed ID: 16751280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease.
    Ma Q; Yang J; Li T; Milner TA; Hempstead BL
    Neurobiol Dis; 2015 Oct; 82():466-477. PubMed ID: 26282324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease.
    Keene CD; Rodrigues CM; Eich T; Chhabra MS; Steer CJ; Low WC
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10671-6. PubMed ID: 12149470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease.
    Pineda JR; Canals JM; Bosch M; Adell A; Mengod G; Artigas F; Ernfors P; Alberch J
    J Neurochem; 2005 Jun; 93(5):1057-68. PubMed ID: 15934928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
    Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
    Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Striatal infusion of glial conditioned medium diminishes huntingtin pathology in r6/1 mice.
    Perucho J; Casarejos MJ; Gómez A; Ruíz C; Fernández-Estevez MÁ; Muñoz MP; de Yébenes JG; Mena MÁ
    PLoS One; 2013; 8(9):e73120. PubMed ID: 24069174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease.
    Giampà C; Middei S; Patassini S; Borreca A; Marullo F; Laurenti D; Bernardi G; Ammassari-Teule M; Fusco FR
    Eur J Neurosci; 2009 Mar; 29(5):902-10. PubMed ID: 19291221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
    Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
    Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice.
    Simmons DA; Mehta RA; Lauterborn JC; Gall CM; Lynch G
    Neurobiol Dis; 2011 Feb; 41(2):436-44. PubMed ID: 20977939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.
    Palazuelos J; Aguado T; Pazos MR; Julien B; Carrasco C; Resel E; Sagredo O; Benito C; Romero J; Azcoitia I; Fernández-Ruiz J; Guzmán M; Galve-Roperh I
    Brain; 2009 Nov; 132(Pt 11):3152-64. PubMed ID: 19805493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington's disease.
    Dey ND; Bombard MC; Roland BP; Davidson S; Lu M; Rossignol J; Sandstrom MI; Skeel RL; Lescaudron L; Dunbar GL
    Behav Brain Res; 2010 Dec; 214(2):193-200. PubMed ID: 20493905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human amniotic mesenchymal stem cells and their paracrine factors promote wound healing by inhibiting heat stress-induced skin cell apoptosis and enhancing their proliferation through activating PI3K/AKT signaling pathway.
    Li JY; Ren KK; Zhang WJ; Xiao L; Wu HY; Liu QY; Ding T; Zhang XC; Nie WJ; Ke Y; Deng KY; Liu QW; Xin HB
    Stem Cell Res Ther; 2019 Aug; 10(1):247. PubMed ID: 31399039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The longevity-associated variant of BPIFB4 improves a CXCR4-mediated striatum-microglia crosstalk preventing disease progression in a mouse model of Huntington's disease.
    Di Pardo A; Ciaglia E; Cattaneo M; Maciag A; Montella F; Lopardo V; Ferrario A; Villa F; Madonna M; Amico E; Carrizzo A; Damato A; Pepe G; Marracino F; Auricchio A; Vecchione C; Maglione V; Puca AA
    Cell Death Dis; 2020 Jul; 11(7):546. PubMed ID: 32683420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease.
    Hsiao HY; Chiu FL; Chen CM; Wu YR; Chen HM; Chen YC; Kuo HC; Chern Y
    Hum Mol Genet; 2014 Aug; 23(16):4328-44. PubMed ID: 24698979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease.
    DeMarch Z; Giampà C; Patassini S; Bernardi G; Fusco FR
    Neurobiol Dis; 2008 Jun; 30(3):375-387. PubMed ID: 18424161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
    Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
    Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease.
    Jin J; Peng Q; Hou Z; Jiang M; Wang X; Langseth AJ; Tao M; Barker PB; Mori S; Bergles DE; Ross CA; Detloff PJ; Zhang J; Duan W
    Hum Mol Genet; 2015 May; 24(9):2508-27. PubMed ID: 25609071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.